Search hospitals > Virginia > Richmond
Virginia Cancer Institute
Claim this profileRichmond, Virginia 23230
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Pancreatic Cancer
Conducts research for Cancer
174 reported clinical trials
21 medical researchers
Summary
Virginia Cancer Institute is a medical facility located in Richmond, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Cancer and other specialties. Virginia Cancer Institute is involved with conducting 174 clinical trials across 185 conditions. There are 21 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Khalid Matin.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Andrew Poklepovic, MDVirginia Commonwealth University/Massey Cancer Center5 years of reported clinical research
Expert in Cancer
Expert in Melanoma
36 reported clinical trials
85 drugs studied
Sarah W. Gordon, DOVirginia Commonwealth University/Massey Cancer Center9 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
54 drugs studied
Leslie Randall, MDVCU Massey Cancer Center at Stony Point2 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
19 reported clinical trials
35 drugs studied
Khalid MatinVirginia Commonwealth University/Massey Cancer Center6 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
14 reported clinical trials
30 drugs studied
Clinical Trials running at Virginia Cancer Institute
Breast Cancer
Lung Cancer
Breast cancer
Ovarian Cancer
Cancer
Multiple Myeloma
Esophageal cancer
Non-Small Cell Lung Cancer
Cutaneous Melanoma
Myelofibrosis
Gedatolisib + Fulvestrant +/- Palbociclib
for Advanced Breast Cancer
This trial is testing a combination of drugs to treat advanced breast cancer that has not responded to other treatments. The drugs work by blocking growth signals, breaking down estrogen receptors, and stopping cell division. Tamoxifen is a commonly used drug that blocks estrogen receptors to treat breast cancer, but resistance to it often develops.
Recruiting2 awards Phase 311 criteria
sac-TMT + Pembrolizumab
for Breast Cancer
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Recruiting2 awards Phase 35 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Virginia Cancer Institute?
Virginia Cancer Institute is a medical facility located in Richmond, Virginia. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Cancer and other specialties. Virginia Cancer Institute is involved with conducting 174 clinical trials across 185 conditions. There are 21 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Khalid Matin.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.